NASDAQ:DERM - Dermira Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $10.58 -0.15 (-1.40 %) (As of 07/18/2018 04:59 AM ET)Previous Close$10.73Today's Range$10.50 - $10.7852-Week Range$6.98 - $31.42Volume488,000 shsAverage Volume1.31 million shsMarket Capitalization$483.76 millionP/E Ratio-2.44Dividend YieldN/ABeta1.46 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Dermira, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. It has licensing agreements with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate in Japan; and F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California. Receive DERM News and Ratings via Email Sign-up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:DERM CUSIPN/A Webwww.dermira.com Phone650-421-7200 Debt Debt-to-Equity Ratio2.19 Current Ratio5.17 Quick Ratio5.17 Price-To-Earnings Trailing P/E Ratio-2.44 Forward P/E Ratio-2.07 P/E GrowthN/A Sales & Book Value Annual Sales$4.54 million Price / Sales97.53 Cash FlowN/A Price / CashN/A Book Value$3.59 per share Price / Book2.95 Profitability EPS (Most Recent Fiscal Year)($4.39) Net Income$-303,260,000.00 Net Margins-8,823.69% Return on Equity-95.84% Return on Assets-33.21% Miscellaneous Employees162 Outstanding Shares41,850,000Market Cap$483.76 Dermira (NASDAQ:DERM) Frequently Asked Questions What is Dermira's stock symbol? Dermira trades on the NASDAQ under the ticker symbol "DERM." How were Dermira's earnings last quarter? Dermira Inc (NASDAQ:DERM) announced its quarterly earnings data on Thursday, May, 3rd. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by $0.09. The biopharmaceutical company earned $0.30 million during the quarter. Dermira had a negative return on equity of 95.84% and a negative net margin of 8,823.69%. View Dermira's Earnings History. What price target have analysts set for DERM? 6 brokerages have issued 12 month target prices for Dermira's stock. Their forecasts range from $16.00 to $48.00. On average, they expect Dermira's share price to reach $29.6667 in the next year. This suggests a possible upside of 180.4% from the stock's current price. View Analyst Ratings for Dermira. What is the consensus analysts' recommendation for Dermira? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Dermira stock? Here are some recent quotes from research analysts about Dermira stock: 1. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (7/4/2018) 2. Cantor Fitzgerald analysts commented, "We remain positive on DERM’s stock following a group investor dinner we held on 3/26/18 with COO & CFO Andrew Guggenhime and VP of IR Ian Clements." (3/27/2018) 3. Mizuho analysts commented, "We can attest that Dermira has been investing in pre-launch activities and had a strong presence at the AAD 2018 conference across all three of its key assets in acne, hyperhidrosis, and atopic dermatitis. We summarize 4Q:17 results in Exhibit 1 below. We reiterate our Buy rating in front of the binary acne read-out, which if positive, could drive significant upside to the stock. Data are expected in 1Q:18." (2/23/2018) Who are some of Dermira's key competitors? Some companies that are related to Dermira include Cambrex (CBM), Mallinckrodt (MNK), Aimmune Therapeutics (AIMT), PTC Therapeutics (PTCT), AnaptysBio (ANAB), Corcept Therapeutics (CORT), IMMURON Ltd/S (IMRN), Biohaven Pharmaceutical (BHVN), ARMO Biosciences (ARMO), Innoviva (INVA), Pacira Pharmaceuticals (PCRX), Uniqure (QURE), TherapeuticsMD (TXMD), Theravance Biopharma (TBPH) and Arrowhead Pharmaceuticals (ARWR). Who are Dermira's key executives? Dermira's management team includes the folowing people: Mr. Thomas G. Wiggans, Co-Founder, CEO & Chairman (Age 66)Dr. Eugene Andrew Bauer, Co-Founder, Chief Medical Officer & Director (Age 76)Mr. Andrew L. Guggenhime, Chief Financial Officer (Age 50)Mr. Luis C. Peña, Chief Devel. Officer (Age 55)Ms. Lori Lyons-Williams, Chief Commercial Officer (Age 41) Has Dermira been receiving favorable news coverage? News coverage about DERM stock has trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dermira earned a media sentiment score of 0.17 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 47.56 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term. Who are Dermira's major shareholders? Dermira's stock is owned by a number of of institutional and retail investors. Top institutional investors include Fox Run Management L.L.C. (0.06%) and Xact Kapitalforvaltning AB (0.03%). Company insiders that own Dermira stock include Andrew Guggenhime, Christopher M Griffith, David E Cohen, Eugene A Bauer, Fred B Craves, Thomas G Wiggans and William R Ringo. View Institutional Ownership Trends for Dermira. Which institutional investors are selling Dermira stock? DERM stock was sold by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C.. Company insiders that have sold Dermira company stock in the last year include Christopher M Griffith, David E Cohen, Eugene A Bauer and Thomas G Wiggans. View Insider Buying and Selling for Dermira. Which institutional investors are buying Dermira stock? DERM stock was acquired by a variety of institutional investors in the last quarter, including Xact Kapitalforvaltning AB. Company insiders that have bought Dermira stock in the last two years include Fred B Craves and Thomas G Wiggans. View Insider Buying and Selling for Dermira. How do I buy shares of Dermira? Shares of DERM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Dermira's stock price today? One share of DERM stock can currently be purchased for approximately $10.58. How big of a company is Dermira? Dermira has a market capitalization of $483.76 million and generates $4.54 million in revenue each year. The biopharmaceutical company earns $-303,260,000.00 in net income (profit) each year or ($4.39) on an earnings per share basis. Dermira employs 162 workers across the globe. How can I contact Dermira? Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected] MarketBeat Community Rating for Dermira (NASDAQ DERM)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 207 (Vote Outperform)Underperform Votes: 175 (Vote Underperform)Total Votes: 382MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe DERM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DERM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: Should I follow buy, hold and sell recommendations?